BASILDON, England: Catumaxomab Received a Positive Opinion From the EMA’s Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If Approved Catumaxomab Will Be the Only Approved Drug Treatment of Malignant Ascites Pharmanovia Will Lead All Activities to Launch Catumaxomab This Is Pharmanovia’s First Monoclonal …
